Resistance management of Obinutuzumab

Obinutuzumab is a drug used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its main mode of action is antibody-dependent cellular cytotoxicity(ADCC). Understanding the resistance mechanism to otuzumab is very important for the development of next-step strategies for subsequent otuzumab-containing treatments, including otuzumab re-treatment. However, some patients may develop resistance to otuzumab.

Resistance may be related to individual genetic variations. Through genetic testing, doctors can choose a more suitable treatment plan based on the patient's genetic characteristics. If a patient develops resistance to otuzumab, doctors can consider switching to other anti-cancer drugs or combining them with other drugs to improve the therapeutic effect. This may include the use of chemotherapy drugs, other targeted therapies, immunomodulators, etc. Sometimes, changing the dose or frequency of otuzumab may slow or reverse resistance. But this needs to be done under the guidance of a doctor and requires an assessment of the patient's overall health and possible side effects. However, everyone’s physique is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be around 9,000 yuan, which is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.